Artículos de revistas sobre el tema "High-grade serous ovarian carcinoma"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "High-grade serous ovarian carcinoma".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Casey, Laura y Naveena Singh. "Ovarian High-Grade Serous Carcinoma". Surgical Pathology Clinics 12, n.º 2 (junio de 2019): 515–28. http://dx.doi.org/10.1016/j.path.2019.01.007.
Texto completoPannu, Harpreet K., Weining Ma, Emily Craig Zabor, Chaya S. Moskowitz, Richard R. Barakat y Hedvig Hricak. "Enhancement of Ovarian Malignancy on Clinical Contrast Enhanced MRI Studies". ISRN Obstetrics and Gynecology 2013 (13 de febrero de 2013): 1–8. http://dx.doi.org/10.1155/2013/979345.
Texto completoKshirsagar, Malti, Wei Jiang y Ie-Ming Shih. "DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression". Journal of Oncology 2012 (2012): 1–7. http://dx.doi.org/10.1155/2012/621685.
Texto completoVang, Russell, Ie-Ming Shih y Robert J. Kurman. "Ovarian Low-grade and High-grade Serous Carcinoma". Advances in Anatomic Pathology 16, n.º 5 (septiembre de 2009): 267–82. http://dx.doi.org/10.1097/pap.0b013e3181b4fffa.
Texto completoMoss, Esther Louise, Tim Evans, Philippa Pearmain, Sarah Askew, Kavita Singh, Kiong K. Chan, Raji Ganesan y Lynn Hirschowitz. "Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?" International Journal of Gynecologic Cancer 25, n.º 7 (septiembre de 2015): 1201–7. http://dx.doi.org/10.1097/igc.0000000000000477.
Texto completoVoutsadakis, Ioannis A. "Low-grade serous ovarian carcinoma: an evolution toward targeted therapy". International Journal of Gynecologic Cancer 30, n.º 10 (27 de noviembre de 2019): 1619–26. http://dx.doi.org/10.1136/ijgc-2019-000832.
Texto completoKenda Šuster, Nataša, Snježana Frković Grazio, Irma Virant-Klun, Ivan Verdenik y Špela Smrkolj. "Cancer Stem Cell–Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases". International Journal of Gynecologic Cancer 27, n.º 9 (noviembre de 2017): 2006–13. http://dx.doi.org/10.1097/igc.0000000000001105.
Texto completoRicciardi, Enzo, Thaïs Baert, Beyhan Ataseven, Florian Heitz, Sonia Prader, Mareike Bommert, Stephanie Schneider, Andreas du Bois y Philipp Harter. "Low-grade Serous Ovarian Carcinoma". Geburtshilfe und Frauenheilkunde 78, n.º 10 (octubre de 2018): 972–76. http://dx.doi.org/10.1055/a-0717-5411.
Texto completoDe Leo, Antonio, Donatella Santini, Claudio Ceccarelli, Giacomo Santandrea, Andrea Palicelli, Giorgia Acquaviva, Federico Chiarucci et al. "What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors". Diagnostics 11, n.º 4 (14 de abril de 2021): 697. http://dx.doi.org/10.3390/diagnostics11040697.
Texto completoWu, Jingjing y Jian-Jun Wei. "HMGA2 and high-grade serous ovarian carcinoma". Journal of Molecular Medicine 91, n.º 10 (19 de mayo de 2013): 1155–65. http://dx.doi.org/10.1007/s00109-013-1055-8.
Texto completoBajaj, Anubha. "The Flagellate Transition- Serous Carcinoma Ovary". Women's Health Science Journal 6, n.º 1 (2022): 1–4. http://dx.doi.org/10.23880/whsj-16000166.
Texto completoSeidman, Jeffrey D., Anna Yemelyanova, Jonathan A. Cosin, Anthony Smith y Robert J. Kurman. "Survival Rates for International Federation of Gynecology and Obstetrics Stage III Ovarian Carcinoma by Cell Type: A Study of 262 Unselected Patients With Uniform Pathologic Review". International Journal of Gynecologic Cancer 22, n.º 3 (marzo de 2012): 367–71. http://dx.doi.org/10.1097/igc.0b013e31823c6f80.
Texto completoBoyd, Clinton y W. Glenn McCluggage. "Low-Grade Ovarian Serous Neoplasms (Low-Grade Serous Carcinoma and Serous Borderline Tumor) Associated With High-Grade Serous Carcinoma or Undifferentiated Carcinoma". American Journal of Surgical Pathology 36, n.º 3 (marzo de 2012): 368–75. http://dx.doi.org/10.1097/pas.0b013e31823732a9.
Texto completoPunzón-Jiménez, Paula, Victor Lago, Santiago Domingo, Carlos Simón y Aymara Mas. "Molecular Management of High-Grade Serous Ovarian Carcinoma". International Journal of Molecular Sciences 23, n.º 22 (9 de noviembre de 2022): 13777. http://dx.doi.org/10.3390/ijms232213777.
Texto completoCojocaru, E., C. A. Parkinson y J. D. Brenton. "Personalising Treatment for High-Grade Serous Ovarian Carcinoma". Clinical Oncology 30, n.º 8 (agosto de 2018): 515–24. http://dx.doi.org/10.1016/j.clon.2018.05.008.
Texto completoSANTILLAN, A., Y. W. KIM, M. L. ZAHURAK, G. J. GARDNER, R. L. GIUNTOLI, I. M. SHIH y R. E. BRISTOW. "Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma". International Journal of Gynecological Cancer 17, n.º 3 (mayo de 2007): 601–6. http://dx.doi.org/10.1111/j.1525-1438.2007.00820.x.
Texto completoGokadze, Nadezhda, Vladimir Selchuk, G. Krasnoshchekova, Yuliya Payanidi, Svetlana Vinokurova y Kirill Zhordania. "IMMUNOCYTOCHEMICAL ANALYSIS OF ASPIRATION MATERIAL FROM THE UTERINE SEROUS OVARIAN CANCER DETECTION". Problems in oncology 66, n.º 2 (1 de febrero de 2020): 160–66. http://dx.doi.org/10.37469/0507-3758-2020-66-2-160-166.
Texto completoKohn, Elise C. y S. Percy Ivy. "Whence High-Grade Serous Ovarian Cancer". American Society of Clinical Oncology Educational Book, n.º 37 (mayo de 2017): 443–48. http://dx.doi.org/10.1200/edbk_174718.
Texto completoOkoye, Ekene, Elizabeth D. Euscher y Anais Malpica. "Ovarian Low-grade Serous Carcinoma". American Journal of Surgical Pathology 40, n.º 5 (mayo de 2016): 627–35. http://dx.doi.org/10.1097/pas.0000000000000615.
Texto completoGross, Amy L., Robert J. Kurman, Russell Vang, Ie-Ming Shih y Kala Visvanathan. "Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics". Journal of Oncology 2010 (2010): 1–9. http://dx.doi.org/10.1155/2010/126295.
Texto completoKoshiyama, Masafumi, Noriomi Matsumura y Ikuo Konishi. "Recent Concepts of Ovarian Carcinogenesis: Type I and Type II". BioMed Research International 2014 (2014): 1–11. http://dx.doi.org/10.1155/2014/934261.
Texto completoKepuladze, Shota, Tamar Dzotsenidze, Arsen Gvenetadze, Mariam Gachechiladze y George Burkadze. "Immunohistochemical phenotype of fallopian tubes in patients with different grades of serous ovarian carcinoma". Indian Journal of Pathology and Oncology 9, n.º 4 (15 de diciembre de 2022): 301–5. http://dx.doi.org/10.18231/j.ijpo.2022.073.
Texto completoDowson, Cassandra B., Colin Stewart, Sarah O'Sullivan, Nicholas Pachter, Lyn Schofield y Paul A. Cohen. "Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas". International Journal of Gynecologic Cancer 30, n.º 1 (7 de noviembre de 2019): 94–99. http://dx.doi.org/10.1136/ijgc-2019-000540.
Texto completoGeorgescu, Tiberiu-Augustin, Roxana Bohiltea, Octavian Munteanu, Corina Grigoriu, Ioana Paunica y Maria Sajin. "A mini-review regarding the carcinogenesis and morphology of serous tumors of the ovary, fallopian tube and peritoneum". Journal of Mind and Medical Sciences 8, n.º 1 (15 de abril de 2021): 44–52. http://dx.doi.org/10.22543/7674.81.p4452.
Texto completoSalvador, Shannon, Blake Gilks, Martin Köbel, David Huntsman, Barry Rosen y Dianne Miller. "The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas". International Journal of Gynecologic Cancer 19, n.º 1 (2009): 58–64. http://dx.doi.org/10.1111/igc.0b013e318199009c.
Texto completoStur, Elaine, Sara Corvigno, Mingchu Xu, Ken Chen, Yukun Tan, Sanghoon Lee, Jinsong Liu et al. "Spatially resolved transcriptomics of high-grade serous ovarian carcinoma". iScience 25, n.º 3 (marzo de 2022): 103923. http://dx.doi.org/10.1016/j.isci.2022.103923.
Texto completoBromley, Amy B., Alon D. Altman, Pamela Chu, Jill G. Nation, Gregg S. Nelson, Praful Ghatage, Steve E. Kalloger, Guangming Han y Martin Köbel. "Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma". International Journal of Gynecological Pathology 31, n.º 5 (septiembre de 2012): 397–404. http://dx.doi.org/10.1097/pgp.0b013e31824c2372.
Texto completoO'Neill, C. J., H. A. McBride, L. E. Connolly, M. T. Deavers, A. Malpica y W. G. McCluggage. "High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour". Histopathology 50, n.º 6 (mayo de 2007): 773–79. http://dx.doi.org/10.1111/j.1365-2559.2007.02682.x.
Texto completoSantandrea, Giacomo, Simonetta Piana, Riccardo Valli, Magda Zanelli, Elisa Gasparini, Antonio De Leo, Vincenzo Dario Mandato y Andrea Palicelli. "Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature". Diagnostics 11, n.º 2 (29 de enero de 2021): 199. http://dx.doi.org/10.3390/diagnostics11020199.
Texto completoNahar, Begum Afrin, Rama Saha, Chhanda Das y Gourishankar Kamilya. "Immunohistochemical expression of human epididymis 4 in ovarian malignancy". International Journal of Research in Medical Sciences 7, n.º 12 (27 de noviembre de 2019): 4493. http://dx.doi.org/10.18203/2320-6012.ijrms20195506.
Texto completoManchana, Tarinee, Ruangsak Lertkhachonsuk y Chinachote Teerapakpinyo. "Somatic BRCA Mutation in High Grade Epithelial Ovarian Cancer Patients". Asian Pacific Journal of Cancer Biology 3, n.º 4 (9 de enero de 2019): 99–103. http://dx.doi.org/10.31557/apjcb.2018.3.4.99-103.
Texto completoLevanon, Keren, Christopher Crum y Ronny Drapkin. "New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact". Journal of Clinical Oncology 26, n.º 32 (10 de noviembre de 2008): 5284–93. http://dx.doi.org/10.1200/jco.2008.18.1107.
Texto completoKim, Jaeyeon, Eun Park, Olga Kim, Jeanne Schilder, Donna Coffey, Chi-Heum Cho y Robert Bast. "Cell Origins of High-Grade Serous Ovarian Cancer". Cancers 10, n.º 11 (12 de noviembre de 2018): 433. http://dx.doi.org/10.3390/cancers10110433.
Texto completoKhatun, Dr Most Fatema, Dr Md Zahangir Alam, Dr Md Bani Amin, Dr Milan Kumar Saha, Dr Shamima Hamid y Dr Md Samsuzzaman Khan. "Study on P53 Expression in Association with Histopathological Grading of Ovarian Serous Carcinoma". Scholars Journal of Applied Medical Sciences 9, n.º 10 (24 de octubre de 2021): 1584–90. http://dx.doi.org/10.36347/sjams.2021.v09i10.019.
Texto completoUlianova, E. P., E. M. Nepomnyashchaya, G. V. Zhukova, A. B. Sagakyants, D. Yu Yakubova y O. G. Shulgina. "ABC transporters in the development of platinum drug resistance in serous ovarian carcinoma". CLINICAL AND EXPERIMENTAL MORPHOLOGY 11, n.º 2 (2022): 13–21. http://dx.doi.org/10.31088/cem2022.11.2.13-21.
Texto completoSALANI, R., R. J. KURMAN, R. GIUNTOLI, G. GARDNER, R. BRISTOW, T. L. WANG y I. M. SHIH. "Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance". International Journal of Gynecologic Cancer 18, n.º 3 (mayo de 2008): 487–91. http://dx.doi.org/10.1111/j.1525-1438.2007.01039.x.
Texto completoEstrella, Jeannelyn S., Judith K. Wolf y Michael T. Deavers. "Ovarian Serous Carcinoma Associated With a Distinct “Corded and Hyalinized” Pattern". Archives of Pathology & Laboratory Medicine 137, n.º 2 (1 de febrero de 2013): 275–79. http://dx.doi.org/10.5858/arpa.2011-0200-cr.
Texto completoMorency, Elizabeth, Mario M. Leitao y Robert A. Soslow. "Low-Stage High-Grade Serous Ovarian Carcinomas". International Journal of Gynecological Pathology 35, n.º 3 (mayo de 2016): 222–29. http://dx.doi.org/10.1097/pgp.0000000000000256.
Texto completoOsman Mohamed, Aisha, Nazik Elmalaika Husain, Rawia Eljaili Elmassry, Lubna Alnageeb, Mohammed Elhassan y Mohammed Siddig Abdelaziz. "Immunohistochemical expression of p53 in Type I and II epithelial ovarian cancer among Sudanese women: a cross-sectional study". F1000Research 8 (10 de octubre de 2019): 1739. http://dx.doi.org/10.12688/f1000research.20608.1.
Texto completoParis, Elizabeth A., Janice M. Bahr, Sanjib Basu y Animesh Barua. "Changes in Nucleolin Expression during Malignant Transformation Leading to Ovarian High-Grade Serous Carcinoma". Cancers 15, n.º 3 (21 de enero de 2023): 661. http://dx.doi.org/10.3390/cancers15030661.
Texto completoCho, Kathleen R. "Ovarian Cancer Update: Lessons From Morphology, Molecules, and Mice". Archives of Pathology & Laboratory Medicine 133, n.º 11 (1 de noviembre de 2009): 1775–81. http://dx.doi.org/10.5858/133.11.1775.
Texto completoZhang, Li, Po Ding, Hongcheng Lv, Dan Zhang, Guang Liu, Zhengduo Yang, Yan Li, Jun Liu y Shiwu Zhang. "Number of Polyploid Giant Cancer Cells and Expression of EZH2 Are Associated with VM Formation and Tumor Grade in Human Ovarian Tumor". BioMed Research International 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/903542.
Texto completoDergham, Ana Paula, Caroline Busatta Vaz de Paula, Seigo Nagashima, Márcia Olandoski, Lucia de Noronha y Vanessa Santos Sotomaior. "Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study". Journal of Personalized Medicine 13, n.º 7 (26 de junio de 2023): 1045. http://dx.doi.org/10.3390/jpm13071045.
Texto completoKutlvasr, K., K. Bukovjan y R. Kodet. "Bilateral low grade serous adenocarcinoma of the ovaries in a badger (Meles meles L.) and its association with a borderline serous ovarian tumour: a case report". Veterinární Medicína 59, No. 1 (14 de febrero de 2014): 44–50. http://dx.doi.org/10.17221/7245-vetmed.
Texto completoKhashaba, Marwa, Reham Nagib, azza abdelaziz, Ghada Eladawy y Mohammed Mohamed. "Clinicopathological and Immunohistochemical Study of High Grade Serous Ovarian Carcinoma". Medicine Updates 2, n.º 2 (1 de julio de 2020): 15–37. http://dx.doi.org/10.21608/muj.2020.29356.1011.
Texto completoKurman, R. J. "Origin and molecular pathogenesis of ovarian high-grade serous carcinoma". Annals of Oncology 24 (diciembre de 2013): x16—x21. http://dx.doi.org/10.1093/annonc/mdt463.
Texto completoChen, Gregory M., Lavanya Kannan, Ludwig Geistlinger, Victor Kofia, Zhaleh Safikhani, Deena M. A. Gendoo, Giovanni Parmigiani, Michael Birrer, Benjamin Haibe-Kains y Levi Waldron. "Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma". Clinical Cancer Research 24, n.º 20 (3 de julio de 2018): 5037–47. http://dx.doi.org/10.1158/1078-0432.ccr-18-0784.
Texto completoSingh, Naveena, W. Glenn McCluggage y C. Blake Gilks. "High-grade serous carcinoma of tubo-ovarian origin: recent developments". Histopathology 71, n.º 3 (18 de julio de 2017): 339–56. http://dx.doi.org/10.1111/his.13248.
Texto completoMessini, Irini, Triada Doulgeraki, Dimitris Chrysanthakis, Petros Yiannou, Theofani Gavresea, Christos Papadimitriou, Theodoros Panoskaltsis, Zannis Voulgaris, Athanassios Vlachos y Kitty Pavlakis. "Assessing the landscape of ovarian serous borderline tumors". International Journal of Gynecologic Cancer 29, n.º 3 (18 de enero de 2019): 572–78. http://dx.doi.org/10.1136/ijgc-2018-000086.
Texto completoGilks, C. Blake. "Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma". Journal of Oncology 2010 (2010): 1–7. http://dx.doi.org/10.1155/2010/740968.
Texto completo